Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

BACKGROUND: Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cell lung cancer (NSCLC) patients treated with nivol...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemeijer, Anna-Larissa Nadia, Sahba, Sara, Smit, Egbert Frederik, Lissenberg-Witte, Birgit Ilja, de Langen, Adrianus Johannes, Thunnissen, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403301/
https://www.ncbi.nlm.nih.gov/pubmed/32433601
http://dx.doi.org/10.1038/s41416-020-0888-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403301/
https://www.ncbi.nlm.nih.gov/pubmed/32433601
http://dx.doi.org/10.1038/s41416-020-0888-5

Ejemplares similares